Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
初始抗 CD19 CAR T 细胞疗法对复发/难治性 LBCL 患者后续抗 CD22 CAR T 细胞生产和临床结果的影响
阅读：6
作者：Su Yi-Jiun, Kramer Anne Marijn, Hamilton Mark P, Agarwal Neha, Srinagesh Hrishikesh K, Baird John H, Sahaf Bita, Kuo Adam, Ehlinger Zachary J, Desai Moksha H, Rietberg Skyler P, Tunuguntla Ramya, Patel Shabnum, Chinnasamy Harshini, Gkitsas-Long Nikolaos, Klysz Dorota D, Brown Annie Kathleen, Bharadwaj Sushma, Dahiya Saurabh, Smith Melody, Muffly Lori, Mackall Crystal L, Good Zinaida, Feldman Steven A, Miklos David B, Frank Matthew J
| 期刊： | Cancer Discovery | 影响因子： | 33.300 |
| 时间： | 2025 | 起止号： | 2025 Apr 2; 15(4):733-747 |
| doi： | 10.1158/2159-8290.CD-24-1071 | 研究方向： | 细胞生物学 |
特别声明
1、本文转载旨在传播信息，不代表本网站观点，亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用，必须保留本网站注明的“来源”，并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载，或需洽谈转载稿费等事宜，请及时与本网站联系。
4、此外，如需投稿，也可通过邮箱info@biocloudy.com与我们取得联系。